Login

Melissa M. Carmichael

ORCID: 0009-0009-3461-0740
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5026451386
Research Areas
  • Phytochemicals and Medicinal Plants
  • Cancer Cells and Metastasis
  • DNA Repair Mechanisms
  • Heat shock proteins research
  • Mitochondrial Function and Pathology

Dartmouth College
 2025

Bridgewater State University
 2023

 Oxidative Phosphorylation is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer
OPENALEX - Publications 
Steven Tau Mary D. Chamberlin Huijuan Yang Jonathan D. Marotti Patricia C. Muskus and 12 more Alyssa M. Roberts Melissa M. Carmichael Lauren Cressey Christo Philip C. Dragnev Eugene Demidenko Riley A. Hampsch Shannon M. Soucy Fred Kolling Kimberley S. Samkoe James V. Alvarez Arminja N. Kettenbach Todd W. Miller

Abstract Despite adjuvant treatment with endocrine therapies, estrogen receptor-positive (ER+) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential. Therefore, strategies targeting such may prevent recurrent disease. Using CRISPR-Cas9 genome-wide knockout screening ER+ cells, we identified survival mechanism involving metabolic reprogramming reliance...

10.1158/0008-5472.can-24-1204 article EN Cancer Research 2025-01-08
 Suppl. Figure 6 from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER<sup>+</sup> Breast Cancer
OPENALEX - Publications 
Steven Tau Mary D. Chamberlin Huijuan Yang Jonathan D. Marotti Patricia C. Muskus and 12 more Alyssa M. Roberts Melissa M. Carmichael Lauren Cressey Christo Philip C. Dragnev Eugene Demidenko Riley A. Hampsch Shannon M. Soucy Fred Kolling Kimberley S. Samkoe James V. Alvarez Arminja N. Kettenbach Todd W. Miller

&lt;p&gt;Suppl. Figure 6&lt;/p&gt;

10.1158/0008-5472.28595211 preprint EN cc-by 2025-03-14
 Suppl. Figure 1 from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER<sup>+</sup> Breast Cancer
OPENALEX - Publications 
Steven Tau Mary D. Chamberlin Huijuan Yang Jonathan D. Marotti Patricia C. Muskus and 12 more Alyssa M. Roberts Melissa M. Carmichael Lauren Cressey Christo Philip C. Dragnev Eugene Demidenko Riley A. Hampsch Shannon M. Soucy Fred Kolling Kimberley S. Samkoe James V. Alvarez Arminja N. Kettenbach Todd W. Miller

&lt;p&gt;Suppl. Figure 1&lt;/p&gt;

10.1158/0008-5472.28595229 preprint EN cc-by 2025-03-14
 Suppl. Figure 4 from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER<sup>+</sup> Breast Cancer
OPENALEX - Publications 
Steven Tau Mary D. Chamberlin Huijuan Yang Jonathan D. Marotti Patricia C. Muskus and 12 more Alyssa M. Roberts Melissa M. Carmichael Lauren Cressey Christo Philip C. Dragnev Eugene Demidenko Riley A. Hampsch Shannon M. Soucy Fred Kolling Kimberley S. Samkoe James V. Alvarez Arminja N. Kettenbach Todd W. Miller

&lt;p&gt;Suppl. Figure 4&lt;/p&gt;

10.1158/0008-5472.28595217 preprint EN cc-by 2025-03-14
 Suppl. Figure 2 from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER<sup>+</sup> Breast Cancer
OPENALEX - Publications 
Steven Tau Mary D. Chamberlin Huijuan Yang Jonathan D. Marotti Patricia C. Muskus and 12 more Alyssa M. Roberts Melissa M. Carmichael Lauren Cressey Christo Philip C. Dragnev Eugene Demidenko Riley A. Hampsch Shannon M. Soucy Fred Kolling Kimberley S. Samkoe James V. Alvarez Arminja N. Kettenbach Todd W. Miller

&lt;p&gt;Suppl. Figure 2&lt;/p&gt;

10.1158/0008-5472.28595226 preprint EN cc-by 2025-03-14
 Suppl. Figure 5 from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER<sup>+</sup> Breast Cancer
OPENALEX - Publications 
Steven Tau Mary D. Chamberlin Huijuan Yang Jonathan D. Marotti Patricia C. Muskus and 12 more Alyssa M. Roberts Melissa M. Carmichael Lauren Cressey Christo Philip C. Dragnev Eugene Demidenko Riley A. Hampsch Shannon M. Soucy Fred Kolling Kimberley S. Samkoe James V. Alvarez Arminja N. Kettenbach Todd W. Miller

&lt;p&gt;Suppl. Figure 5&lt;/p&gt;

10.1158/0008-5472.28595214 preprint EN cc-by 2025-03-14
 Supplementary Data from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER<sup>+</sup> Breast Cancer
OPENALEX - Publications 
Steven Tau Mary D. Chamberlin Huijuan Yang Jonathan D. Marotti Patricia C. Muskus and 12 more Alyssa M. Roberts Melissa M. Carmichael Lauren Cressey Christo Philip C. Dragnev Eugene Demidenko Riley A. Hampsch Shannon M. Soucy Fred Kolling Kimberley S. Samkoe James V. Alvarez Arminja N. Kettenbach Todd W. Miller

&lt;p&gt;Clinical study protocol (version 11October2021)&lt;/p&gt;

10.1158/0008-5472.28595199 preprint EN cc-by 2025-03-14
 Suppl. Figure 8 from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER<sup>+</sup> Breast Cancer
OPENALEX - Publications 
Steven Tau Mary D. Chamberlin Huijuan Yang Jonathan D. Marotti Patricia C. Muskus and 12 more Alyssa M. Roberts Melissa M. Carmichael Lauren Cressey Christo Philip C. Dragnev Eugene Demidenko Riley A. Hampsch Shannon M. Soucy Fred Kolling Kimberley S. Samkoe James V. Alvarez Arminja N. Kettenbach Todd W. Miller

&lt;p&gt;Suppl. Figure 8&lt;/p&gt;

10.1158/0008-5472.28595205 preprint EN cc-by 2025-03-14
 Supplementary Data Figure Legends from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER<sup>+</sup> Breast Cancer
OPENALEX - Publications 
Steven Tau Mary D. Chamberlin Huijuan Yang Jonathan D. Marotti Patricia C. Muskus and 12 more Alyssa M. Roberts Melissa M. Carmichael Lauren Cressey Christo Philip C. Dragnev Eugene Demidenko Riley A. Hampsch Shannon M. Soucy Fred Kolling Kimberley S. Samkoe James V. Alvarez Arminja N. Kettenbach Todd W. Miller

&lt;p&gt;L:egends for Suppl. Figs. 1-8&lt;/p&gt;

10.1158/0008-5472.28595202 preprint EN cc-by 2025-03-14
 Suppl. Figure 3 from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER<sup>+</sup> Breast Cancer
OPENALEX - Publications 
Steven Tau Mary D. Chamberlin Huijuan Yang Jonathan D. Marotti Patricia C. Muskus and 12 more Alyssa M. Roberts Melissa M. Carmichael Lauren Cressey Christo Philip C. Dragnev Eugene Demidenko Riley A. Hampsch Shannon M. Soucy Fred Kolling Kimberley S. Samkoe James V. Alvarez Arminja N. Kettenbach Todd W. Miller

&lt;p&gt;Suppl. Figure 3&lt;/p&gt;

10.1158/0008-5472.28595223 preprint EN cc-by 2025-03-14
 Data from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER<sup>+</sup> Breast Cancer
OPENALEX - Publications 
Steven Tau Mary D. Chamberlin Huijuan Yang Jonathan D. Marotti Patricia C. Muskus and 12 more Alyssa M. Roberts Melissa M. Carmichael Lauren Cressey Christo Philip C. Dragnev Eugene Demidenko Riley A. Hampsch Shannon M. Soucy Fred Kolling Kimberley S. Samkoe James V. Alvarez Arminja N. Kettenbach Todd W. Miller

&lt;div&gt;Abstract&lt;p&gt;Despite adjuvant treatment with endocrine therapies, estrogen receptor–positive (ER&lt;sup&gt;+&lt;/sup&gt;) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential. Therefore, strategies targeting such may prevent recurrent disease. Using CRISPR-Cas9 genome-wide knockout screening ER&lt;sup&gt;+&lt;/sup&gt; cells, we...

10.1158/0008-5472.c.7719705 preprint EN 2025-03-14
 Suppl. Figure 7 from Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER<sup>+</sup> Breast Cancer
OPENALEX - Publications 
Steven Tau Mary D. Chamberlin Huijuan Yang Jonathan D. Marotti Patricia C. Muskus and 12 more Alyssa M. Roberts Melissa M. Carmichael Lauren Cressey Christo Philip C. Dragnev Eugene Demidenko Riley A. Hampsch Shannon M. Soucy Fred Kolling Kimberley S. Samkoe James V. Alvarez Arminja N. Kettenbach Todd W. Miller

&lt;p&gt;Suppl. Figure 7&lt;/p&gt;

10.1158/0008-5472.28595208 preprint EN cc-by 2025-03-14
 The small heat shock protein αB-Crystallin protects versus withaferin A-induced apoptosis and confers a more metastatic phenotype in cisplatin-resistant ovarian cancer cells
OPENALEX - Publications 
Melissa M. Carmichael Israa Alchaar Kathleen A. Davis Merideth Krevosky

Since a majority of ovarian tumors recur in drug-resistant form leaving patients few treatment options, the goal this study was to explore phenotypic and molecular characteristics cisplatin-resistant cancer cell line (OVCAR8R) as compared its cisplatin-sensitive syngeneic counterpart (OVCAR8) effectiveness novel chemotherapeutic, Withaferin A (WA). In addition unique morphological characteristics, small heat shock proteins (Hsps) αB-Crystallin (HspB5) Hsp27 are constitutively expressed along...

10.1371/journal.pone.0281009 article EN cc-by PLoS ONE 2023-01-26
Coming Soon ...